Discontinue Sacubitril-Valsartan Immediately and Switch to Standard ACE Inhibitor or ARB-Based Heart Failure Therapy
If a heart failure patient develops cholestasis while on sacubitril-valsartan (Entresto), you must discontinue the drug immediately and transition to an alternative RAAS inhibitor-based regimen, specifically an ACE inhibitor (ACEI) or angiotensin receptor blocker (ARB), combined with a beta-blocker, mineralocorticoid receptor antagonist (MRA), and SGLT2 inhibitor as tolerated.
Immediate Management Steps
1. Stop Sacubitril-Valsartan
- Discontinue immediately upon recognition of cholestasis
- The FDA label does not specifically list cholestasis as a contraindication, but hepatotoxicity requires immediate cessation 1
- Document the adverse reaction clearly in the medical record to prevent future re-exposure
2. Assess Severity and Etiology
- Confirm cholestasis with liver function tests (elevated alkaline phosphatase, GGT, direct bilirubin)
- Rule out other causes: biliary obstruction, other medications, viral hepatitis, autoimmune conditions
- Check for signs of hepatic decompensation (coagulopathy, encephalopathy, ascites)
- If severe hepatotoxicity is present, consider hepatology consultation
3. Washout Period Considerations
- If switching TO an ACEI: Allow 36 hours washout from last sacubitril-valsartan dose before starting ACEI to minimize angioedema risk 1
- If switching TO an ARB: No washout period required; can start immediately 2
Alternative Heart Failure Regimen
Foundational Four-Pillar GDMT (Without ARNI)
Pillar 1: RAAS Inhibition
First choice: ACE Inhibitor (if no prior intolerance)
Alternative: ARB (if ACEI-intolerant due to cough or prior angioedema)
Pillar 2: Beta-Blocker
- Continue or initiate evidence-based beta-blocker (carvedilol, metoprolol succinate, or bisoprolol)
- These are independent of ARNI and should be maintained 3, 4
- Target heart rate 50-60 bpm if tolerated
Pillar 3: Mineralocorticoid Receptor Antagonist
- Spironolactone 12.5-25 mg daily or eplerenone 25 mg daily
- Essential for mortality reduction in HFrEF 3, 4
- Monitor potassium and creatinine closely, especially when combined with ACEI/ARB
- Consider potassium binders (patiromer) if hyperkalemia develops rather than stopping MRA 5
Pillar 4: SGLT2 Inhibitor
- Dapagliflozin 10 mg daily or empagliflozin 10 mg daily
- Can be started immediately; does not lower BP significantly 6
- Reduces hyperkalemia risk when combined with RAAS inhibitors 5
- Provides mortality and hospitalization benefits independent of other therapies
Monitoring Strategy Post-Transition
First 1-2 Weeks:
- Check BP (supine and standing), heart rate, symptoms
- Assess volume status; adjust diuretics as needed
- Monitor for symptomatic hypotension or orthostasis
At 1-2 Weeks:
- Recheck electrolytes (potassium, sodium), renal function (creatinine, eGFR)
- Liver function tests to ensure cholestasis is resolving
- Uptitrate ACEI/ARB if tolerated
Ongoing (Every 2-4 Weeks During Titration):
- Continue uptitrating ACEI/ARB toward target doses
- Monitor potassium and creatinine with each dose increase
- Accept up to 30% increase in creatinine if stable and non-oliguric 2
- Tolerate potassium up to 5.5 mEq/L with close monitoring 5
Key Clinical Pitfalls to Avoid
Do Not:
- Re-challenge with sacubitril-valsartan after cholestasis—this represents a serious adverse reaction
- Combine ACEI + ARB routinely; only consider if BP uncontrolled and with careful monitoring for hyperkalemia and renal dysfunction 3
- Stop all RAAS inhibition due to mild hyperkalemia or modest creatinine elevation—use strategies to maintain therapy 5
- Delay SGLT2 inhibitor initiation—it reduces hyperkalemia risk and improves outcomes 5
Do:
- Prioritize maintaining GDMT even at lower doses rather than complete withdrawal 5, 6
- Use potassium binders (patiromer) if hyperkalemia limits RAAS inhibitor dosing 5
- Educate patients about transient dizziness/hypotension being expected with life-prolonging medications 6
- Consider rechallenge with ACEI/ARB at lower doses if initially not tolerated—many patients tolerate on retry 5
Special Considerations
If Patient Has Low Blood Pressure (<90 mmHg systolic):
- Start with SGLT2 inhibitor and MRA first (neither significantly lowers BP) 6
- Add low-dose ACEI/ARB with very gradual uptitration
- Sometimes cardiac output improves with GDMT, allowing better BP tolerance over time 6
If Patient Has Renal Dysfunction (eGFR <60):
- Start ACEI/ARB at lowest dose
- More frequent monitoring of potassium and creatinine
- Higher risk of adverse events but still beneficial if carefully managed 5, 2
- SGLT2 inhibitors remain beneficial even with reduced eGFR
If Patient Has Hyperkalemia History:
- SGLT2 inhibitors reduce hyperkalemia risk—start early 5
- Consider prophylactic potassium binder (patiromer) to maintain RAAS inhibition 5
- Dietary potassium restriction counseling
- Avoid potassium-sparing diuretics beyond MRA
Cost and Formulary Considerations:
- Generic ACEIs and ARBs are widely available and inexpensive
- SGLT2 inhibitors may require prior authorization but have strong outcome data
- MRAs (spironolactone) are generic and affordable
This regimen provides comprehensive, evidence-based heart failure management without sacubitril-valsartan, addressing all four pillars of GDMT for HFrEF while avoiding re-exposure to the medication that caused cholestasis 3, 2, 4.